<DOC>
	<DOCNO>NCT02963727</DOCNO>
	<brief_summary>Wharton Jelly derive Mesenchymal Stem Cells ( WJMSC ) inject patient diagnosed Knee osteoarthrosis</brief_summary>
	<brief_title>Use Wharton Jelly Derived Mesenchymal Stem Cells Knee Osteoarthrosis</brief_title>
	<detailed_description>Ten patient gender diagnose Knee osteoarthrosis , enrol accord strict inclusion exclusion criterion . These patient inject Wharton Jelly derive Mesenchymal Stem Cells . Then , follow clinical assessment , laboratory investigation well magnetic resonance imaging ( MRI ) inject knee .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Severe KOA stage III IV Laurance &amp; Kellgren stag judge Posterioranterior ( PA ) Xray knee joint . Willing participate signing inform consent 1 . Sublaxation beyond 20 degree bone knee joint 2 . Oral anticoagulant heparin therapy 3 . Heart failure arrhythmia 4 . Body Mass Index &gt; 35 5 . Uncontrolled Diabetes Mellitus . 6 . Evidence Infectious Diseases . 7 . Active infection 8 . Malignancy 9 . Pregnancy 10 . Anemia le 11g/dl thrombocytopenia less 100,000 leucopenia less 3000 . 11 . Unreliable patient 12 . Nonresident Jordan</criteria>
	<gender>All</gender>
	<minimum_age>42 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>osteoarthrosis</keyword>
	<keyword>Knee</keyword>
	<keyword>Wharton Jelly</keyword>
</DOC>